Global Comprehensive Market Intelligence Report
Drug Developer's Intelligence Report
Neurology Drug Report
Report covering World’s Largest Number of Active Neurology Drug Developers till May 2014
RELEASED - MAY 2014
Neurology Drug Developers
First time identifies and profiles 480 Active Neurology focused Drug Development companies.
Creates immense authentic knowledge-base on hundreds of proprietary technologies, M&A deals and partnering occurring in domain in last 10 years.
Neurology Drug Report 2014 (first Edition)
Covers all Aspects of Neurology Drug Development Intelligence
COMPANIES PROFILES * MOLECULES * INDICATIONS * TECHNOLOGIES * DEALS * FUNDING
providing intelligence at fingertips
Worldwide Extensive Coverage
Active 480 Neurology Drug Developer Profiles
800+ Pipeline Molecules Profiles, Drug Target & Mechanism of Action.
With In-depth Market Analysis & Forecast of Individual Indication.
Perfect B2B Solution
Unique first in class Intelligence Report
First Report to cover active 480 companies profiles including Clinical, Pre-Clinical & Discovery Companies, with 800+ active molecules in development for the treatment of various Neurological Disorders.
First Report to cover 19+ Neurological Disease full coverage, from latest pipeline updates & analysis to individual indication’s market size and sales forecast.
First Report to cover all LinkedIn & e-mail IDs of key decision makers (CXOs) in their respective company profiles, that further helps to scales up business development opportunities.
First Report to cover all details of companies covered in the form of 480 mini-reports and includes- past 5 years major business deals, funding, proprietary technologies and drug updates.
First innovative approach that helps to directly identify & link with the key decision maker.
Report is highly precise and designed keeping in mind to keep information intact, informative and self explanatory. Also, every piece of intelligence is cross validated.
Only facts, no guess work.
530+ Pages present complete picture of individual company’s pipeline, deals, partnering, funding etc. and outline individual company’s core strength and stand with respect to other drug developers.
Report documents all Neurology focused news/deals of every drug developers in past 10 years. Making it perfect tool for Decision Making and a big time saver too.
Compares Oranges with Oranges.
Only Active Neurology Drug Developing Companies, with no room to Diagnostic and Device companies; making data clear and impactful.
Most of the intelligence provider covers limited number of known companies, that too many of which have no links to the core title of the report. Also many renowned database too contains acquired/closed companies, thus driving final intelligence too tedious and time consuming exercise.
All our reports provides comprehensive intelligence, with largest active industry coverage and avoids investing money on other similar resources. Thus, saves lots of resources in terms of time and money, in identifying new partnering opportunities.
Each year, we publish very small number of comprehensive reports and are experts in identifying and tracking drug developers. We maintain our own database and track’s every individual company.
From last 10 years, our team exclusively providing marketing intelligence in field of Oncology and Neurology Drug Development.
532 pages full of insights
This report for the first time identifies and profiles 480 Active Neurology focused Drug Development companies from 31 countries worldwide, developing 801 neurological disorders targeting drugs. It evaluates 16 major neurological indications drug development pipeline and analysis it to provide thousands of active clinical trials information; emerging drug targets, molecule types etc. Thus all together brings the most updated and robust information at the fingertips. It creates immense authentic knowledge-base (all information with references) on hundreds of proprietary technologies, M&A deals and partnering occurring in domain in last 10 years.
The 16 Major Indications detailed coverage in the report includes- Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Schizophrenia, Major Depressive Disorder, Amyotrophic Lateral Sclerosis, Ischemic and Hemorrhagic Stroke, Huntington’s Disease, Epilepsy, Pain (Migraine, Neurotropic and Post Hepatic Neuralgia), Neurological Trauma, Anxiety Disorders, ADHD, Addiction, Autism Spectrum Disorder, Bipolar Disorder and other Rare Neurological disorder.
Report covers each individual indication Epidemiology, Treatment options, Top selling drugs and their sales, indication Market size and forecast with detailed drug development Pipeline Analysis covering all Monoclonal Antibodies, Vaccines, Stem Cell Therapies, and Medical Devices in development, it also covers promising technologies and top drug development targets for the indication. Thus making it a versatile Comprehensive Report for Decision-Making.
A Single Innovative and Unique Report provide Answers to Many:
- It provides immense opportunities in identifying emerging cancer companies. It covers active 272 clinical, 208 Preclinical and Discovery stage companies along with their current partners, technologies and cancer drug pipeline.
- It provides LinkedIn and E-mail IDs of all decision makers in individual clinical companies. These thousand’s of focused links helps in saving time and linking to right person to further work on finer details.
- 16 Major Neurological Indication’s Individual Drug Development Pipeline and its Analysis, Market Size and Forecast.
- Rare Neurological Indications Drug development pipelines are also included, separately.
- All Finer Details are further elaborated in the individual 480 Companies Profiles, all written in form of mini reports.
- Offers complete and focused lead identification details for Biosuppliers /CROs.
- The complete 532 Pages report is highly interlinked with all Clinical Trials numbers and last updated status.
- The Text is supplemented with 98 Tables and 36 Figures/Info-graphics.